Ashland (Ashland) Capex-to-Revenue : 0.08 (As of Dec. 2023)

View and export this data going back to 1950. Start your Free Trial

What is Ashland Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Ashland's Capital Expenditure for the three months ended in Dec. 2023 was $-36.00 Mil. Its Revenue for the three months ended in Dec. 2023 was $473.00 Mil.

Hence, Ashland's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.08.

Ashland Capex-to-Revenue Historical Data

The historical data trend for Ashland's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ashland Capex-to-Revenue Chart

Ashland Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Capex-to-Revenue

Get a 7-Day Free Trial

0.07

0.05

0.08

Ashland Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial															0.04	0.06	0.08	0.13	0.08

Competitive Comparison of Ashland's Capex-to-Revenue

For the Specialty Chemicals subindustry, Ashland's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ashland's Capex-to-Revenue Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Ashland's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ashland's Capex-to-Revenue falls into.

Ashland Capex-to-Revenue Calculation

Ashland's Capex-to-Revenue for the fiscal year that ended in Sep. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-170)	/	2191
	=	0.08

Ashland's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-36)	/	473
	=	0.08

Ashland (NYSE:ASH) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Ashland Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ashland's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ashland (Ashland) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Ashland Inc (NYSE:ASH) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

AHT:Germany

Address

8145 Blazer Drive, Wilmington, DE, USA, 19808

Website

http://www.ashland.com

Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. Ashland includes only U.S. and Canada in its North America designation and includes Europe, the Middle East and Africa in its Europe designation.

Executives

Eric N Boni	officer: Principal Accounting Officer	8145 BLAZER DRIVE, WILMINGTON DE 19808
J Kevin Willis	officer: Chief Financial Officer	50 E RIVERCENTER BLVD, COVINGTON KY 41011
James P. Minicucci	officer: SVP Strategy, M&A & Portfolio	5474 RINGS ROAD, NORTH TOWER, 5TH FLOOR, DUBLIN OH 43017
Karl R. Bostaph	officer: SVP Operations	5474 RINGS ROAD, NORTH TOWER, 5TH FLOOR, DUBLIN OH 43017
Robin E. Lampkin	officer: SVP, Gen. Counsel & Secretary	5475 RINGS ROAD, NORTH TOWER, 5TH FLOOR, DUBLIN OH 43017
Sergio Pedreiro	director	2 PARK AVENUE, NEW YORK NY 10016
Eileen Drury	officer: SVP and Chief Human Resources	8145 BLAZER DRIVE, WILMINGTON DE 19808
Ricky C Sandler	director, other: See Remarks	65 EAST 55TH STREET, 25TH FLOOR, NEW YORK NY 10022
Steven D Bishop	director	ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Suzan F. Harrison	director	77 WEST WACKER DRIVE, SUITE 4600, CHICAGO IL 60601
Guillermo Novo	director, officer: Chairman and CEO	AIR PRODUCTS AND CHEMICALS, INC., 7201 HAMILTON BOULEVARD, ALLENTOWN PA 18195
Winkler Von Mohrenfels Petra Yvonne	officer: Sr. VP, GC and Secretary	8145 BLAZER DRIVE, WILMINGTON DE 19808
Min Chong	officer: Sr VP & Gen Mgr, Spc Additives	8145 BLAZER DRIVE, WILMINGTON DE 19808
Osama M Musa	officer: Sr. Vice President	ASHLAND GLOBAL HOLDINGS INC, 1005 ROUTE 202/206, BRIDGEWATER NJ 08807
Swaminathan Ashok Kalyana	officer: Sr VP & Gen Mgr, Life Sciences	8145 BLAZER DRIVE, WILMINGTON DE 19808